Europe Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity
Europe influenza treatment market accounted for $187.6 million in 2019 and will grow by 3.6% annually over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic.
Highlighted with 33 tables and 44 figures, this 100-page report “Europe Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Highlighted with 33 tables and 44 figures, this 100-page report “Europe Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Peramivir
- Zanamivir
- Other Drugs
- Influenza A
- Influenza B
- Influenza C
- Oral Administration
- Other Administration Routes
- Retail Pharmacy
- Hospital Pharmacy
- Clinics
- Online Stores
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 INTRODUCTION
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF EUROPE MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Oseltamivir Phosphate
3.3 Baloxavir Marboxil
3.4 Peramivir
3.5 Zanamivir
3.6 Other Drugs
4 SEGMENTATION OF EUROPE MARKET BY INFLUENZA TYPE
4.1 Market Overview by Influenza Type
4.2 Influenza A
4.3 Influenza B
4.4 Influenza C
5 SEGMENTATION OF EUROPE MARKET BY ADMINISTRATION ROUTE
5.1 Market Overview by Administration Route
5.2 Oral Administration
5.3 Other Administration Routes
6 SEGMENTATION OF EUROPE MARKET BY DISTRIBUTION CHANNEL
6.1 Market Overview by Distribution Channel
6.2 Retail Pharmacy
6.3 Hospital Pharmacy
6.4 Clinics
6.5 Online Stores
7 EUROPEAN MARKET 2019-2030 BY COUNTRY
7.1 Overview of European Market
7.2 Germany
7.3 UK
7.4 France
7.5 Spain
7.6 Italy
7.7 Russia
7.8 Rest of European Market
8 COMPETITIVE LANDSCAPE
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
9 INVESTING IN EUROPE MARKET: RISK ASSESSMENT AND MANAGEMENT
9.1 Risk Evaluation of Europe Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF EUROPE MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Oseltamivir Phosphate
3.3 Baloxavir Marboxil
3.4 Peramivir
3.5 Zanamivir
3.6 Other Drugs
4 SEGMENTATION OF EUROPE MARKET BY INFLUENZA TYPE
4.1 Market Overview by Influenza Type
4.2 Influenza A
4.3 Influenza B
4.4 Influenza C
5 SEGMENTATION OF EUROPE MARKET BY ADMINISTRATION ROUTE
5.1 Market Overview by Administration Route
5.2 Oral Administration
5.3 Other Administration Routes
6 SEGMENTATION OF EUROPE MARKET BY DISTRIBUTION CHANNEL
6.1 Market Overview by Distribution Channel
6.2 Retail Pharmacy
6.3 Hospital Pharmacy
6.4 Clinics
6.5 Online Stores
7 EUROPEAN MARKET 2019-2030 BY COUNTRY
7.1 Overview of European Market
7.2 Germany
7.3 UK
7.4 France
7.5 Spain
7.6 Italy
7.7 Russia
7.8 Rest of European Market
8 COMPETITIVE LANDSCAPE
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
9 INVESTING IN EUROPE MARKET: RISK ASSESSMENT AND MANAGEMENT
9.1 Risk Evaluation of Europe Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products
LIST OF TABLES
Table 1. Snapshot of Europe Influenza Treatment Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in Europe Influenza Treatment Market
Table 3. Europe Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 4. Europe Influenza Treatment Market by Influenza Type, 2019-2030, $ mn
Table 5. Europe Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 6. Europe Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 7. Europe Influenza Treatment Market by Country, 2019-2030, $ mn
Table 8. Germany Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 9. Germany Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 10. Germany Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 11. UK Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 12. UK Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 13. UK Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 14. France Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 15. France Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 16. France Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 17. Spain Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 18. Spain Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 19. Spain Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 20. Italy Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 21. Italy Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 22. Italy Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 23. Russia Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 24. Russia Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 25. Russia Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 26. Influenza Treatment Market in Rest of Europe by Country, 2019-2030, $ mn
Table 27. AstraZeneca Plc: Company Snapshot
Table 28. AstraZeneca Plc: Business Segmentation
Table 29. AstraZeneca Plc: Product Portfolio
Table 30. AstraZeneca Plc: Revenue, 2016-2018, $ mn
Table 31. AstraZeneca Plc: Recent Developments
Table 32. Risk Evaluation for Investing in Europe Market, 2019-2030
Table 33. Critical Success Factors and Key Takeaways
Table 1. Snapshot of Europe Influenza Treatment Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in Europe Influenza Treatment Market
Table 3. Europe Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 4. Europe Influenza Treatment Market by Influenza Type, 2019-2030, $ mn
Table 5. Europe Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 6. Europe Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 7. Europe Influenza Treatment Market by Country, 2019-2030, $ mn
Table 8. Germany Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 9. Germany Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 10. Germany Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 11. UK Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 12. UK Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 13. UK Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 14. France Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 15. France Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 16. France Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 17. Spain Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 18. Spain Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 19. Spain Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 20. Italy Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 21. Italy Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 22. Italy Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 23. Russia Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 24. Russia Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 25. Russia Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 26. Influenza Treatment Market in Rest of Europe by Country, 2019-2030, $ mn
Table 27. AstraZeneca Plc: Company Snapshot
Table 28. AstraZeneca Plc: Business Segmentation
Table 29. AstraZeneca Plc: Product Portfolio
Table 30. AstraZeneca Plc: Revenue, 2016-2018, $ mn
Table 31. AstraZeneca Plc: Recent Developments
Table 32. Risk Evaluation for Investing in Europe Market, 2019-2030
Table 33. Critical Success Factors and Key Takeaways
LIST OF FIGURES
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Europe Influenza Treatment Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Europe Influenza Treatment Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of Europe Influenza Treatment Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of Europe Influenza Treatment Market
Figure 13. Breakdown of Europe Influenza Treatment Market by Product Type, 2019-2030, % of Revenue
Figure 14. Europe Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%)
Figure 15. Europe Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn
Figure 16. Europe Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn
Figure 17. Europe Influenza Treatment Market: Peramivir, 2019-2030, $ mn
Figure 18. Europe Influenza Treatment Market: Zanamivir, 2019-2030, $ mn
Figure 19. Europe Influenza Treatment Market: Other Drugs, 2019-2030, $ mn
Figure 20. Breakdown of Europe Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue
Figure 21. Europe Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%)
Figure 22. Europe Influenza Treatment Market: Influenza A, 2019-2030, $ mn
Figure 23. Europe Influenza Treatment Market: Influenza B, 2019-2030, $ mn
Figure 24. Europe Influenza Treatment Market: Influenza C, 2019-2030, $ mn
Figure 25. Breakdown of Europe Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue
Figure 26. Europe Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%)
Figure 27. Europe Influenza Treatment Market: Oral Administration, 2019-2030, $ mn
Figure 28. Europe Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn
Figure 29. Breakdown of Europe Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue
Figure 30. Europe Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%)
Figure 31. Europe Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn
Figure 32. Europe Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn
Figure 33. Europe Influenza Treatment Market: Clinics, 2019-2030, $ mn
Figure 34. Europe Influenza Treatment Market: Online Stores, 2019-2030, $ mn
Figure 35. Breakdown of European Influenza Treatment Market by Country, 2019 and 2030, % of Revenue
Figure 36. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 37. Influenza Treatment Market in Germany, 2019-2030, $ mn
Figure 38. Influenza Treatment Market in UK, 2019-2030, $ mn
Figure 39. Influenza Treatment Market in France, 2019-2030, $ mn
Figure 40. Influenza Treatment Market in Spain, 2019-2030, $ mn
Figure 41. Influenza Treatment Market in Italy, 2019-2030, $ mn
Figure 42. Influenza Treatment Market in Russia, 2019-2030, $ mn
Figure 43. Influenza Treatment Market in Rest of Europe, 2019-2030, $ mn
Figure 44. Growth Stage of Europe Influenza Treatment Industry over the Forecast Period
COMPANIES MENTIONED
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Europe Influenza Treatment Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Europe Influenza Treatment Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of Europe Influenza Treatment Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of Europe Influenza Treatment Market
Figure 13. Breakdown of Europe Influenza Treatment Market by Product Type, 2019-2030, % of Revenue
Figure 14. Europe Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%)
Figure 15. Europe Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn
Figure 16. Europe Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn
Figure 17. Europe Influenza Treatment Market: Peramivir, 2019-2030, $ mn
Figure 18. Europe Influenza Treatment Market: Zanamivir, 2019-2030, $ mn
Figure 19. Europe Influenza Treatment Market: Other Drugs, 2019-2030, $ mn
Figure 20. Breakdown of Europe Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue
Figure 21. Europe Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%)
Figure 22. Europe Influenza Treatment Market: Influenza A, 2019-2030, $ mn
Figure 23. Europe Influenza Treatment Market: Influenza B, 2019-2030, $ mn
Figure 24. Europe Influenza Treatment Market: Influenza C, 2019-2030, $ mn
Figure 25. Breakdown of Europe Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue
Figure 26. Europe Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%)
Figure 27. Europe Influenza Treatment Market: Oral Administration, 2019-2030, $ mn
Figure 28. Europe Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn
Figure 29. Breakdown of Europe Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue
Figure 30. Europe Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%)
Figure 31. Europe Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn
Figure 32. Europe Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn
Figure 33. Europe Influenza Treatment Market: Clinics, 2019-2030, $ mn
Figure 34. Europe Influenza Treatment Market: Online Stores, 2019-2030, $ mn
Figure 35. Breakdown of European Influenza Treatment Market by Country, 2019 and 2030, % of Revenue
Figure 36. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 37. Influenza Treatment Market in Germany, 2019-2030, $ mn
Figure 38. Influenza Treatment Market in UK, 2019-2030, $ mn
Figure 39. Influenza Treatment Market in France, 2019-2030, $ mn
Figure 40. Influenza Treatment Market in Spain, 2019-2030, $ mn
Figure 41. Influenza Treatment Market in Italy, 2019-2030, $ mn
Figure 42. Influenza Treatment Market in Russia, 2019-2030, $ mn
Figure 43. Influenza Treatment Market in Rest of Europe, 2019-2030, $ mn
Figure 44. Growth Stage of Europe Influenza Treatment Industry over the Forecast Period
COMPANIES MENTIONED
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
